Register for our free email digests:
Division of Pfizer Inc.
Latest From Wyeth-Ayerst International
Additional preclinical studies provided FDA with reassurance during a second-cycle review that lorcaserin was unlikely to trigger the valvular heart disease associated with dexfenfluramine and fenfluramine.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Bernard Poussot, Pres.
Robert Power, VP, Global Mktg.
- Contact Info
Phone: (610) 688-4400
150 Radnor-Chester Road
St. Davids, PA 19087
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.